September 20, 2024. Dr. Zuhal Butuner, chief medical officer at Sepul Bio, talks with host Ben Shaberman about her company's two emerging RNA therapies – sepofarsen (for LCA10) and ultevursen (for USH2A) – formerly in clinical trials sponsored by ProQR. Dr. Butuner discusses how the RNA treatments work, what was learned from earlier clinical trials, and Sepul Bio's plans to move the therapies back into human studies.
